Class II โ€” Potential Health Hazard

Potential health hazard โ€” use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Amoxicillin and Clavulanate Potassium for Oral Suspension USP Recalled by Teva Pharmaceuticals USA, Inc Due to Subpotent drug; Clavulanate Potassium component

Date: October 13, 2025
Company: Teva Pharmaceuticals USA, Inc
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Teva Pharmaceuticals USA, Inc directly.

Affected Products

Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.

Quantity: 4680 cartons

Why Was This Recalled?

Subpotent drug; Clavulanate Potassium component

Where Was This Sold?

This product was distributed to 3 states: CA, MS, OH

Affected (3 states)Not affected

About Teva Pharmaceuticals USA, Inc

Teva Pharmaceuticals USA, Inc has 20 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report